Mayur Mulchand Shah

Mayur Mulchand Shah

Director Director DIN 09074862
DIN 09074862 First appointment Mar 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2021
Shareholding value •••• Premium profile

About Mayur Mulchand Shah

Data last updated:

Mayur Mulchand Shah was a Director at Arogyam Medihub Private Limited (2021–2022) and Director at Avsplus Pharma Private Limited (2021–2023). The companies operate in Pharma.

DIN 09074862
Primary Designation Director
Industry Pharma
First Appointment 04 Mar 2021

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Arogyam Medihub Private Limited U52190MH2021PTC356357
Director04 Mar 20212021Active
Avsplus Pharma Private Limited U51909MH2021PTC356814
Director11 Mar 20212021₹50.81 Cr (FY 2023)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Arogyam Medihub Private Limited
Avsplus Pharma Private Limited
Premium access

Shareholding and investment profile for Mayur Mulchand Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mayur Mulchand Shah

Mayur Mulchand Shah was first appointed on 04 Mar 2021 as Director at Arogyam Medihub Private Limited.

Mayur Mulchand Shah held 2 earlier board appointments: Arogyam Medihub Private Limited (Director, 04 Mar 2021 to 08 Aug 2022); Avsplus Pharma Private Limited (Director, 11 Mar 2021 to 10 May 2023).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available